1 asive assessment of transmural and selective
endomyocardial and epimyocardial perfusion.
2 patients who were monitored with the use of
endomyocardial biopsies (0.5 vs. 3.0, P<0.001).
3 -CD68) and histopathologic criteria found on
endomyocardial biopsies (EMB).
4 on after heart transplant (HT), surveillance
endomyocardial biopsies (EMBs) are often continued for y
5 To determine the utility of surveillance
endomyocardial biopsies (EMBs) during a 14-day OKT3 indu
6 e total Treg population, we examined Treg in
endomyocardial biopsies (EMBs) of both patients who deve
7 d for the presence of viral genome in serial
endomyocardial biopsies (EMBs) using polymerase chain re
8 ited utilization and the poor sensitivity of
endomyocardial biopsies (especially for patchy diseases
9 Percentage of
endomyocardial biopsies (grade 3a, 3b, and 4) with respe
10 ig), and their receptor CXCR3 in consecutive
endomyocardial biopsies (n = 133) from human cardiac all
11 Antigen expression was detected on
endomyocardial biopsies (n = 50) and spleen (n = 11) by
12 ion of VEGF by immunohistochemistry in human
endomyocardial biopsies (n=101) from 10 cardiac transpla
13 ation relies on histopathological grading of
endomyocardial biopsies according to International Socie
14 Endomyocardial biopsies and blood samples from 38 patien
15 METHODS AND
Endomyocardial biopsies and blood samples were obtained
16 We reviewed the simultaneously obtained
endomyocardial biopsies and intravascular ultrasound (IV
17 We evaluated PIMI in the first four weekly
endomyocardial biopsies and/or autopsy myocardium from 1
18 Repeat
endomyocardial biopsies are frequently needed to diagnos
19 the major limitations, and currently, serial
endomyocardial biopsies are required to diagnose rejecti
20 VEGF is expressed in normal human
endomyocardial biopsies at low levels and is induced (sc
21 We analyzed 169 sequential human
endomyocardial biopsies by immunocytochemistry for infil
22 were also found to be clonally explanted in
endomyocardial biopsies collected 17 and 21 mo earlier f
23 cular atheroma excised at endarterectomy and
endomyocardial biopsies contained purely variant fibrino
24 schemic changes in early posttransplantation
endomyocardial biopsies correlate with the later develop
25 GF) mRNA expression was determined in serial
endomyocardial biopsies during the first year after tran
26 Endomyocardial biopsies from 19 old patients with a dila
27 ir receptors CXCR3 and CCR5 was tested in 60
endomyocardial biopsies from 24 patients using quantitat
28 Right ventricular
endomyocardial biopsies from 30 cases of allograft rejec
29 ern of vascular cardiac allograft rejection,
endomyocardial biopsies from 344 heart transplant recipi
30 D We analyzed pretreatment and posttreatment
endomyocardial biopsies from 58 Fabry patients enrolled
31 Autopsy specimens from 5 patients and
endomyocardial biopsies from 7 patients were used for th
32 estigated in both cultured keratinocytes and
endomyocardial biopsies from affected individuals.
33 the presence of acute cellular rejection in
endomyocardial biopsies from cardiac transplant recipien
34 ve RT-PCR in RNA from right ventricular (RV)
endomyocardial biopsies from intact nonfailing hearts, a
35 properties of mCSCs and vCSCs isolated from
endomyocardial biopsies from patients with advanced hear
36 d (P=0.012) and 5.1-fold (P=0.038) higher in
endomyocardial biopsies from patients with CVB3-positive
37 ntiated adult heart muscle cells, studies in
endomyocardial biopsies from patients with dilated and i
38 luorescence, and immunoperoxidase studies of
endomyocardial biopsies from such patients often reveal
39 erum samples were retrospectively matched to
endomyocardial biopsies in 98 cardiac transplant recipie
40 Protocol
endomyocardial biopsies in all three patients revealed n
41 +) T cells and the CXCR3 ligand IP-10 within
endomyocardial biopsies is strongly associated with acut
42 in pathologic processes, Egr-1 expression in
endomyocardial biopsies may act as a surrogate marker of
43 ry deposition of C4d or C3d were detected in
endomyocardial biopsies of 14 of the 33 patients.
44 Egr-1 protein expression was analyzed in
endomyocardial biopsies of different rejection grades by
45 PAR2 expression in
endomyocardial biopsies of patients with nonischemic car
46 myocardial fibrosis has been detected in the
endomyocardial biopsies of survivors.
47 ling of protein-coding genes and 754 miRs in
endomyocardial biopsies of test cohorts was performed at
48 We performed
endomyocardial biopsies of the RV side of the septum and
49 ere-derived cells (CDCs) isolated from human
endomyocardial biopsies reduce infarct size and improve
50 Analysis of serial
endomyocardial biopsies revealed that high levels of end
51 A total of 240 heart transplant
endomyocardial biopsies were assessed.
52 To determine whether ischemic changes in
endomyocardial biopsies were associated with complement
53 A total of 132 blood specimens and
endomyocardial biopsies were collected from 35 patients,
54 Endomyocardial biopsies were collected with a bioptome f
55 Serial
endomyocardial biopsies were evaluated for cellular reje
56 Endomyocardial biopsies were evaluated within 2 weeks of
57 Porcine
endomyocardial biopsies were harvested and plated as org
58 Autologous cardiospheres or CDCs grown from
endomyocardial biopsies were injected through thoracotom
59 Serial radionuclide ventriculography and
endomyocardial biopsies were performed at baseline, 3, a
60 tegory (1R) appears to have brought together
endomyocardial biopsies with different underlying proces
61 eactivity was not detectable in four of five
endomyocardial biopsies with normal histology.
62 with histologically proven amyloid (374 with
endomyocardial biopsies) and 360 patients subsequently c
63 ranscriptional profiling was performed on 26
endomyocardial biopsies, and expression patterns were co
64 Annual coronary angiograms, serial
endomyocardial biopsies, and serum cardiac troponin-T co
65 ression profiling or with the use of routine
endomyocardial biopsies, in addition to clinical and ech
66 Serial cardiac monitoring, including
endomyocardial biopsies, was performed.
67 Egr-1 mRNA expression and rejection grade in
endomyocardial biopsies.
68 men was used, and rejection was monitored by
endomyocardial biopsies.
69 nd arteriolar endothelial ICAM-1 in matching
endomyocardial biopsies.
70 were measured in 186 patients undergoing 365
endomyocardial biopsies.
71 ents could obviate the need for surveillance
endomyocardial biopsies.
72 in human atrial tissue and right ventricular
endomyocardial biopsies.
73 After a low-grade
endomyocardial biopsy (0 or 1A), one or more donor-recip
74 Endomyocardial biopsy (EMB) has a low sensitivity.
75 diac magnetic resonance (CMR) mapping versus
endomyocardial biopsy (EMB) has not been determined.
76 d many to question the yield of surveillance
endomyocardial biopsy (EMB) in heart transplantation (HT
77 Endomyocardial biopsy (EMB) is a low risk procedure in a
78 The
endomyocardial biopsy (EMB) is considered the gold stand
79 Endomyocardial biopsy (EMB) is often considered when the
80 ue of the distinction between CS and IGCM on
endomyocardial biopsy (EMB) is unknown.
81 tic resonance (CMR), cardiac biomarkers, and
endomyocardial biopsy (EMB) results to predict left vent
82 Use of left ventricular (LV)
endomyocardial biopsy (EMB) to investigate cardiomyopath
83 tients who had blood samples obtained during
endomyocardial biopsy (EMB).
84 uring subsequent cardiac surgery (n = 3) and
endomyocardial biopsy (n = 1).
85 (n = 26), coronary angiography (n = 32), and
endomyocardial biopsy (n = 32).
86 rdiac tissues obtained from autopsies (n=3),
endomyocardial biopsy (n=1), or cardiac transplants (n=2
87 rol had antibody-mediated rejection (AMR) by
endomyocardial biopsy (P<0.01).
88 There was a decrease in the use of
endomyocardial biopsy (P=0.03) and an increase in the us
89 y correlated with inflammatory cell count on
endomyocardial biopsy (r=0.56; P<0.05).
90 retrospectively identified who had undergone
endomyocardial biopsy and cardiac MR at one institution
91 d clinically suspected myocarditis underwent
endomyocardial biopsy and CMR at 1.5 Tesla.
92 Acute allograft rejection was diagnosed by
endomyocardial biopsy and graded according to the Intern
93 disorder has led to the possible overuse of
endomyocardial biopsy and immunosuppressive agents.
94 transplant recipients underwent simultaneous
endomyocardial biopsy and intravascular ultrasound (IVUS
95 nts require more invasive procedures such as
endomyocardial biopsy and may aid in reducing the number
96 ave myocarditis according to the findings on
endomyocardial biopsy and the Dallas histopathological c
97 Rejection was diagnosed using
endomyocardial biopsy and were graded according to stand
98 ant recipients who were referred for routine
endomyocardial biopsy and/or surveillance coronary angio
99 itivity or specificity needed to replace the
endomyocardial biopsy as a diagnostic tool.
100 jection in humans might obviate the need for
endomyocardial biopsy as well as improve the accuracy of
101 including TD imaging, along with transmural
endomyocardial biopsy at the time of coronary bypass sur
102 sis of 196 consecutive patients referred for
endomyocardial biopsy because of clinical suspicion of c
103 All underwent an
endomyocardial biopsy before randomization, which reveal
104 Endomyocardial biopsy can demonstrate fibro-fatty replac
105 In some patients, cardiac MRI and
endomyocardial biopsy can help identify myocarditis, pre
106 that transcriptomic biomarkers from a single
endomyocardial biopsy can improve the clinical detection
107 nological factors at the time of a low-grade
endomyocardial biopsy can predict progression to high-gr
108 Among 74 patients with
endomyocardial biopsy diagnosis of FD cardiomyopathy, 13
109 transplant recipients following inadvertent
endomyocardial biopsy disruption of the tricuspid appara
110 nological factors at the time of a low-grade
endomyocardial biopsy enables prospective stratification
111 Endomyocardial biopsy fibrosis was quantitatively measur
112 Endomyocardial biopsy has defined rejection in clinical
113 The
endomyocardial biopsy has defined the diagnosis of rejec
114 The
endomyocardial biopsy has long been the preferred techni
115 Endomyocardial biopsy has stood the test of time as a su
116 nce of significant rejection on the basis of
endomyocardial biopsy histology.
117 ed recently as potential substitutes for the
endomyocardial biopsy in detecting rejection.
118 nvasive test holds promise for replacing the
endomyocardial biopsy in heart transplant recipients and
119 9 (terminal pathway), at the time of routine
endomyocardial biopsy in heart transplant recipients.
120 This article reviews the current role of the
endomyocardial biopsy in the management of patients foll
121 The sensitivity of transvenous
endomyocardial biopsy increased from 68% (19/28 patients
122 e DNA from the donor genome at times when an
endomyocardial biopsy independently established the pres
123 Percutaneous
endomyocardial biopsy is a widely used and valuable proc
124 The
endomyocardial biopsy is also limited by sub-optimal int
125 Endomyocardial biopsy is currently the standard method u
126 Risk of
endomyocardial biopsy is highest in sick children with s
127 Endomyocardial biopsy is the major method for detecting
128 Endomyocardial biopsy is the standard method of monitori
129 Endomyocardial biopsy is used routinely for diagnosing a
130 The sensitivity of
endomyocardial biopsy may be increased, especially in su
131 rranted to characterize patients with TCM by
endomyocardial biopsy more clearly.
132 METHODS AND
Endomyocardial biopsy NOD2 mRNA expression was higher in
133 Nine episodes of CAVB occurred during
endomyocardial biopsy or coronary angiography, and four
134 Results were correlated with
endomyocardial biopsy rejection grades.
135 Cardiac catheterization and
endomyocardial biopsy remain the "gold standard" for dia
136 Endomyocardial biopsy remains the gold standard for in v
137 etection of transplant rejection by repeated
endomyocardial biopsy requires catheterization and entai
138 fraction to < or = 40%, and one because her
endomyocardial biopsy result was grade 1.5.
139 The therapeutic and prognostic benefits of
endomyocardial biopsy results have recently been demonst
140 Endomyocardial biopsy revealed active myocarditis in 16
141 Endomyocardial biopsy revealed more advanced grade C and
142 in patients with new-onset HF from a single
endomyocardial biopsy sample.
143 Endomyocardial biopsy samples and clinical data were col
144 The current study investigated
endomyocardial biopsy samples from patients with TCM and
145 Levels of TSP-1 mRNA in
endomyocardial biopsy samples of human cardiac allograft
146 Immunohistochemistry of
endomyocardial biopsy samples revealed altered expressio
147 entification of infiltration and fibrosis in
endomyocardial biopsy samples to assess transplant rejec
148 In cases of myocarditis (n=7),
endomyocardial biopsy samples were analyzed by PCR and c
149 Serial LV
endomyocardial biopsy samples were obtained at each echo
150 Serial LV
endomyocardial biopsy samples were obtained to measure c
151 Matching
endomyocardial biopsy samples were screened immunohistoc
152 Among a total of 350
endomyocardial biopsy samples, 180 were identified as id
153 nd arterial endothelial ICAM-1 expression in
endomyocardial biopsy samples.
154 ulation of SA CMCs was isolated from porcine
endomyocardial biopsy samples.
155 F) were correlated with clinical outcome and
endomyocardial biopsy scores.
156 diac fibrosis was assessed histologically on
endomyocardial biopsy sections.
157 Endomyocardial biopsy showed mononuclear infiltrates and
158 lar rejection grading scheme for heart graft
endomyocardial biopsy specimens (EMBs).
159 Standard morphological features of
endomyocardial biopsy specimens do not necessarily corre
160 A total of 157
endomyocardial biopsy specimens from 26 patients with he
161 Three hundred sixteen serial
endomyocardial biopsy specimens from 30 heart transplant
162 Endomyocardial biopsy specimens from 40 patients with pr
163 We studied
endomyocardial biopsy specimens from 7 sex-mismatched (f
164 as is expressed on myocytes, we investigated
endomyocardial biopsy specimens from cardiac transplant
165 okine and receptor gene expression in serial
endomyocardial biopsy specimens from heart transplant pa
166 e-transcriptase polymerase chain reaction in
endomyocardial biopsy specimens from human heart transpl
167 Serial sections of individual
endomyocardial biopsy specimens from patients histologic
168 Percutaneous
endomyocardial biopsy specimens grown in primary culture
169 In addition, studies of
endomyocardial biopsy specimens have furthered our under
170 d percent fibrosis were determined in serial
endomyocardial biopsy specimens obtained from 1 month up
171 Immunocytochemistry was performed on serial
endomyocardial biopsy specimens to evaluate endothelial
172 Endomyocardial biopsy specimens were evaluated during th
173 to receive CDCs, autologous cells grown from
endomyocardial biopsy specimens were infused into the in
174 ologous CDCs (12.5 to 25 x 10(6)) grown from
endomyocardial biopsy specimens were infused via the int
175 B19V DNA and messenger RNA from
endomyocardial biopsy specimens, bone marrow specimens,
176 the isolation of adult human stem cells from
endomyocardial biopsy specimens.
177 expression was increased during rejection in
endomyocardial biopsy specimens.
178 +/- standard deviation) consecutive routine
endomyocardial biopsy surveillance visits during the fir
179 Gal-3 levels and inflammatory cell count on
endomyocardial biopsy was observed in patients with iCMP
180 m each patient were examined for AECA and an
endomyocardial biopsy was performed at regular intervals
181 Endomyocardial biopsy was performed in 9 of the 12 ARVD/
182 methods for the detection of rejection, the
endomyocardial biopsy will remain important in the manag
183 inical safety of any such approach, invasive
endomyocardial biopsy will remain the gold standard.
184 ized that the transcriptome obtained from an
endomyocardial biopsy would yield clinically relevant an
185 hs, 64% occurred within 3 months of the last
endomyocardial biopsy, 96% had normal biopsies, and the
186 ter nucleic acids had been extracted from an
endomyocardial biopsy, an explant, or autopsy samples, P
187 echocardiogram, right ventricular angiogram,
endomyocardial biopsy, and 24-hour ambulatory ECG.
188 criptomic signature, generated from a single
endomyocardial biopsy, could serve as a novel prognostic
189 Myocardial tissue from
endomyocardial biopsy, explant, or autopsy was analyzed
190 ve addressed important issues concerning the
endomyocardial biopsy, including the reliability of the
191 Endomyocardial biopsy, lymphocyte-growth assays, and ant
192 ere positive, concomitantly with a low-grade
endomyocardial biopsy, the positive predictive value for
193 ionship between MDR1/ABCB1 polymorphisms and
endomyocardial biopsy-proven rejection (EBPR) determined
194 the standard method of tissue histology from
endomyocardial biopsy.
195 Nine patients underwent
endomyocardial biopsy.
196 and serial echocardiography; five underwent
endomyocardial biopsy.
197 gs in the diagnosis of amyloidosis proven by
endomyocardial biopsy.
198 assessed by the rejection grade on the first
endomyocardial biopsy.
199 osis on the basis of clinical evaluation and
endomyocardial biopsy.
200 of MMF trough level at the time of scheduled
endomyocardial biopsy.
201 c transplants revolves around the use of the
endomyocardial biopsy.
202 DSE at the time of their regularly scheduled
endomyocardial biopsy.
203 ransplantation (ISHLT) grade 2R or higher at
endomyocardial biopsy.
204 ic work-up, including genetic evaluation and
endomyocardial biopsy.
205 lantation at the time of serial surveillance
endomyocardial biopsy.
206 nical signs and symptoms and low accuracy of
endomyocardial biopsy.
207 ditis was defined by ongoing inflammation on
endomyocardial biopsy.
208 Twenty-eight (88%) patients underwent
endomyocardial biopsy.
209 ars) had undergone diagnostic cardiac MR and
endomyocardial biopsy.
210 mic myocardial (18)F-NOS PET/CT, followed by
endomyocardial biopsy.
211 nd immunoglobulins) and microvasculopathy in
endomyocardial biopsy.
212 cally, the diagnosis of myocarditis required
endomyocardial biopsy.
213 en shown to correlate with the results of an
endomyocardial biopsy.
214 For
endomyocardial-
biopsy grades 1B or 2, a positive lymphoc
215 munohistochemical analysis of a conventional
endomyocardial-
biopsy sample appears to be a highly sens
216 Endomyocardial-
biopsy specimens were evaluated for evide
217 echocardiograms, hemodynamic parameters, and
endomyocardial biopsys from 137 patients with heart tran
218 XFM using external fiducial markers to guide
endomyocardial cell injections in infarcted swine hearts
219 e rise to an inflammatory process leading to
endomyocardial damage and scar formation.
220 Percutaneous
endomyocardial drug delivery is feasible with the aid of
221 ocardial perfusion reserve (MPR) and resting
endomyocardial/
epimyocardial perfusion ratio (Endo/Epi r
222 Tropical
endomyocardial fibrosis (EMF) is a neglected disease of
223 Two patients with
endomyocardial fibrosis were maintained on imatinib 300
224 ncentrations of Gal-3 do not seem to reflect
endomyocardial Gal-3 levels or cardiac fibrosis.
225 evaluate the outcome and prevalence of viral
endomyocardial infection after cardiac transplantation.
226 Viral
endomyocardial infection is an independent predictor of
227 howed <5% apoptotic mononuclear cells in the
endomyocardial infiltrates.
228 ophysiologic mechanisms include systemic and
endomyocardial inflammation with fibrosis.
229 external fiducial markers accurately targets
endomyocardial injection in a swine model of myocardial
230 ed to receive 5, 15, or 30 mg of JVS-100 via
endomyocardial injection.
231 od Manufacturing Practice, were delivered by
endomyocardial injections guided by left ventricular ele
232 Endomyocardial injections of iron-labeled mesenchymal st
233 More than 50
endomyocardial injections were performed with the aid of
234 regional denervation 3 d after placement of
endomyocardial laser channels.
235 but not pravastatin, decreased the degree of
endomyocardial mononuclear cell infiltration seen with R
236 Twenty-six patients (81%) were diagnosed by
endomyocardial or surgical biopsies and 6 at autopsy or
237 Delivery and tracking of
endomyocardial stem cells are limited by the inability t
238 y be able to improve the diagnostic yield of
endomyocardial ventricular biopsy.